Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
DS-234 is a fusion protein that is a highly selective and potent agonist of CD200R, an immune-regulatory receptor thought to be an important immunological checkpoint, with a pivotal role in maintenance of immune tolerance.
Lead Product(s): DS-234
Therapeutic Area: Dermatology Product Name: DS-234
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Arcutis Biotherapeutics
Deal Size: $400.0 million Upfront Cash: $16.0 million
Deal Type: Acquisition September 08, 2022
Details:
DS-234 offers a potential best-in-class profile, as well as a highly complementary treatment option to roflumilast cream which is in late-stage development for atopic dermatitis.
Lead Product(s): DS-234
Therapeutic Area: Dermatology Product Name: DS-234
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Arcutis Biotherapeutics
Deal Size: $30.0 million Upfront Cash: $16.0 million
Deal Type: Acquisition September 07, 2022
Details:
SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.
Lead Product(s): SDC-1801
Therapeutic Area: Dermatology Product Name: SDC-1801
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
Votucalis is a broad-acting histamine inhibitor that was discovered through the same research program that yielded Akari’s lead drug, nomacopan, a complement and leukotriene inhibitor currently in Phase III clinical development.
Lead Product(s): Votucalis
Therapeutic Area: Dermatology Product Name: Votucalis
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
Under the license, Sanofi will develop and commercialise an oral therapy for the treatment of inflammatory diseases. The IL-17 family of cytokines are inducers of inflammation in variety of autoimmune diseases including psoriasis, psoriatic arthritis & ankylosing spondylitis.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $433.2 million Upfront Cash: $7.3 million
Deal Type: Licensing Agreement April 12, 2021
